Showing results (111-120 of 132) with videos related to
Sort By:
Pageof 14
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 11, 2025
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral DiseaseKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.Journal of Gastroenterology|June 13, 2023
Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitisHiroyuki Yoshida, Masahiro Shiokawa, Takeshi Kuwada, et al.Journal of Gastroenterology|January 27, 2023
Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinomaTakeshi Tanaka, Atsuhiro Masuda, Jun Inoue, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.BJS Open|August 2, 2024
Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort studyMasahiro Ohira, Gaku Aoki, Yasushi Orihashi, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 24, 2025
Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular CarcinomaYuta Inoue, Yoshihiko Yano, Saeko Kushida, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and BevacizumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter AnalysisTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.Journal of Gastroenterology and Hepatology|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.Pageof 14